Any investors would pay particular attention to the profitability of a company before considering taking a position. Here we’ll take a quick look at shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) and the company’s ability to generate profit. The firm currently has a Return on Equity -55.40% which is derived from comparing 12-months net income to shareholder equity. So even though the company is generating profits, where can the stock go from here? Sell-side analysts covering the shares are projecting a one year price target of $10.69 on the stock. When comparing this to a recent price of $5.95, the potential upside should be noted. Taking analyst recommendations into consideration results in a Buy/Sell consensus recommendation of 1.90. This is according to all of the analysts polled by First Call.
What makes a stock profitable? Let’s look at a few factors.
Rising EPS (Earnings Per Share)
Businesses must be able to have competitive advantages and must produce value to consumers in the form of desirable goods and services. When a business has a strong brand, they can afford to raise prices and also have a differentiated product that is more desirable compared to their competition. A business that is able to grow earnings per share can afford to pay a rising dividend. Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s trailing 12-months EPS is -1.42.
Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s performance this year to date is 19.72%. The stock has performed 2.94% over the last seven days, 2.23% over the last thirty, and -17.59% over the last three months. Over the last six months, Amicus Therapeutics, Inc.’s stock has been -1.82% and -19.81% for the year.
RSI and Recommendations
Amicus Therapeutics, Inc.’s RSI is 50.92. Based on the stock’s volatility for the week, which is a statistical measure of the dispersion of returns for a given stock and represents average daily high/low percentage range of 7.31% and month of 6.31%.
There are a number of sell-side analysts who have recently weighed in on the firm. As stated earlier, the consensus target price is $10.69 with a mean recommendation of 1.90 (1-5 scale).
Nothing contained in this publication is intended to constitute legal, tax, securities, or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.